FDA Approves New Daily HIV Pill for 15,000 Americans

For people who've spent years juggling handfuls of HIV pills every day, life just got a whole lot simpler.

The FDA approved Bixlenvo, a once-daily HIV pill from Gilead that combines two powerful medicines into one tablet. It's designed for patients whose virus is already under control but who can't use existing single-pill options due to drug resistance, side effects, or interactions with other medications.

About 5% of Americans living with HIV fall into this category. That's roughly 15,000 people who currently manage complicated pill schedules just to stay healthy.

"Some had to take handfuls of pills around 25 years ago," said Dr. Jared Baeten, Gilead's clinical development head. Many of these patients are older adults who've been fighting HIV for decades and managing additional health conditions like heart disease and diabetes.

The new pill combines bictegravir (from Gilead's blockbuster drug Biktarvy) with lenacapavir, a first-in-class treatment that attacks HIV in a unique way. Together, they hit the virus from two different angles, providing strong protection against drug resistance.

Clinical trials tested the pill on patients with long treatment histories. One study enrolled people with a median age of 60 who were taking between 2 and 11 pills daily before switching to Bixlenvo.

The results were encouraging. The single pill kept the virus suppressed just as well as their previous complex regimens after 48 weeks, with no new safety concerns.

Why This Inspires

This approval represents more than just convenience. It's about dignity and quality of life for people who've been managing a chronic disease for decades.

Timothy Cameron, a 64-year-old Seattle resident who's lived with HIV for over 40 years, knows this reality firsthand. He represents a generation that survived when treatment meant handfuls of pills with devastating side effects.

The pill costs $4,595 for a 30-day supply before insurance, similar to other single-tablet HIV treatments. Gilead offers assistance programs for people without insurance and co-pay support for those with commercial coverage.

Beyond this approval, Gilead is building an entire range of HIV treatment options around lenacapavir, including weekly pills and twice-yearly injectable therapies. The goal is giving patients real choices about how they manage their health.

"We're going to build enough options that people can make the choice that's going to work for them," Baeten said. "Some people like the surety of once a day, and some people would want 'set it and forget it' once every six months."

For thousands of Americans who've never given up the fight against HIV, that freedom to choose means everything.